Mirela Dobre is a Nephrology physician affiliated with University Hospitals of Cleveland. OpenAlex indexes 152 publications with 3,658 citations (h-index 33).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11100 Euclid Ave
Cleveland, OH 441061716
Telephone
216-844-8500Provider last certified this registry record 3 Dec 2020.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Otsuka America Pharmaceutical, Inc.Program year20241 payment
- Aurinia Pharma U.S., Inc.Program year20241 payment
- Amgen Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
71.7%Calcium channel blocker16.3%Amlodipine Besylate89%Felodipine Er11%Part D<11 patientsAngiotensin receptor blocker (ARB)12.9%Irbesartan81%Losartan Potassium19%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
16.6%Vitamin D3 Analog6.2%Calcitriol100%Part D≥15 patientsSGLT2 inhibitor2.7%Farxiga100%Part D≥12 patients+ 6 more classes in this area
Musculoskeletal
4.8%Xanthine oxidase inhibitor4.8%Allopurinol100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2018–2025 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Urine Biomarkers for Diabetic Kidney Disease Progression in Participants of the Chronic Renal Insufficiency Cohort Study
Clinical Journal of the American Society of Nephrology
2025 - Progression of Coronary Artery Calcification and Risk of Clinical Events in CKD: The Chronic Renal Insufficiency Cohort Study
American Journal of Kidney Diseases
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Lederman, MD
University Hospitals of Cleveland
Anthony Furlan
University Hospitals of Cleveland
Joseph Sabik, MD
University Hospitals of Cleveland
Hans Luders
University Hospitals of Cleveland
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”